Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.93
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
Adverum Biotechnologies Analyst Ratings and Price Targets | NASDAQ:ADVM | Benzinga
Adverum Biotechnologies Inc has a consensus price target of $24.14 based on the ratings of 7 analysts. The high is $40 issued by Truist Securities on August 14, 2024. The low is $2 issued by Ladenburg Thalmann on March 7, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., RBC Capital, and Truist Securities on November 19, 2024, November 5, 2024, and August 14, 2024, respectively. With an average price target of $26.67 between HC Wainwright & Co., RBC Capital, and Truist Securities, there's an implied 440.91% upside for Adverum Biotechnologies Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
RBC Capital
Truist Securities
Chardan Capital
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Adverum Biotechnologies
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/19/2024 | Buy Now | 508.52% | HC Wainwright & Co. | Matthew Caufield40% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | 102.84% | RBC Capital | Luca Issi42% | $12 → $10 | Maintains | Sector Perform | Get Alert |
| 08/14/2024 | Buy Now | 711.36% | Truist Securities | Joon Lee77% | $60 → $40 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 508.52% | HC Wainwright & Co. | Matthew Caufield40% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 143.41% | RBC Capital | Luca Issi42% | $15 → $12 | Maintains | Sector Perform | Get Alert |
| 07/18/2024 | Buy Now | 711.36% | Chardan Capital | Daniil Gataulin47% | $4 → $40 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 407.1% | Oppenheimer | Francois Brisebois44% | → $25 | Initiates | → Outperform | Get Alert |
| 05/15/2024 | Buy Now | 1117.04% | Truist Securities | Joon Lee77% | $60 → $60 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 508.52% | HC Wainwright & Co. | Matthew Caufield40% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | 508.52% | HC Wainwright & Co. | Matthew Caufield40% | → $30 | Initiates | → Buy | Get Alert |
| 04/29/2024 | Buy Now | 346.25% | Mizuho | Graig Suvannavejh56% | $40 → $22 | Maintains | Buy | Get Alert |
| 03/19/2024 | Buy Now | -18.86% | Chardan Capital | Daniil Gataulin47% | $4 → $40 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | Buy Now | -59.43% | RBC Capital | Luca Issi42% | $30 → $20 | Maintains | Sector Perform | Get Alert |
| 02/06/2024 | Buy Now | -18.86% | Mizuho | Graig Suvannavejh56% | $20 → $40 | Maintains | Buy | Get Alert |
| 11/02/2023 | Buy Now | -59.43% | Mizuho | Graig Suvannavejh56% | → $20 | Initiates | → Buy | Get Alert |
| 09/05/2023 | Buy Now | 21.7% | Truist Securities | Joon Lee77% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | -18.86% | Chardan Capital | Daniil Gataulin47% | $20 → $40 | Upgrade | Neutral → Buy | Get Alert |
| 03/07/2023 | Buy Now | -59.43% | Ladenburg Thalmann | Aydin Huseynov35% | → $20 | Initiates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | -59.43% | Chardan Capital | Daniil Gataulin47% | $25 → $20 | Maintains | Neutral | Get Alert |
| 11/11/2022 | Buy Now | -39.15% | RBC Capital | Luca Issi42% | $50 → $30 | Maintains | Sector Perform | Get Alert |
| 08/12/2022 | Buy Now | -49.29% | Chardan Capital | Daniil Gataulin47% | $30 → $25 | Maintains | Neutral | Get Alert |
| 07/07/2022 | Buy Now | -18.86% | Truist Securities | Joon Lee77% | $30 → $40 | Upgrade | Hold → Buy | Get Alert |
FAQ
What is the target price for Adverum Biotechnologies (ADVM) stock?
The latest price target for Adverum Biotechnologies (NASDAQ:ADVM) was reported by HC Wainwright & Co. on November 19, 2024. The analyst firm set a price target for $30.00 expecting ADVM to rise to within 12 months (a possible 508.52% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adverum Biotechnologies (ADVM)?
The latest analyst rating for Adverum Biotechnologies (NASDAQ:ADVM) was provided by HC Wainwright & Co., and Adverum Biotechnologies reiterated their buy rating.
When was the last upgrade for Adverum Biotechnologies (ADVM)?
The last upgrade for Adverum Biotechnologies Inc happened on August 11, 2023 when Chardan Capital raised their price target to $4. Chardan Capital previously had a neutral for Adverum Biotechnologies Inc.
When was the last downgrade for Adverum Biotechnologies (ADVM)?
There is no last downgrade for Adverum Biotechnologies.
When is the next analyst rating going to be posted or updated for Adverum Biotechnologies (ADVM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on November 19, 2024 so you should expect the next rating to be made available sometime around November 19, 2025.
Is the Analyst Rating Adverum Biotechnologies (ADVM) correct?
While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a reiterated with a price target of $30.00 to $30.00. The current price Adverum Biotechnologies (ADVM) is trading at is $4.93, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.